Verzenios Uniunea Europeană - română - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - sânii neoplasme - agenți antineoplazici - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

FALVAX 250 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

falvax 250 mg

betapharm arzneimittel gmbh - germania - fulvestrantum - sol. inj. in seringa preumpluta - 250mg - antagonisti hormonali si substante inrudite antiestrogeni

VASTALOMA 250 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

vastaloma 250 mg

laboratorios farmalan s.a. - spania - fulvestrantum - sol. inj. in seringa preumpluta - 250mg - antagonisti hormonali si substante inrudite antiestrogeni

FULVESTRANT CIPLA 250 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

fulvestrant cipla 250 mg

laboratorios farmalan, s.a. - spania - fulvestrantum - sol inj. in seringa preumpluta - 250mg - antagonisti hormonali si substante inrudite antiestrogeni